Our partner in Slovenia
Institute of Public Health
Tel. +386 15202776
Fax +386 15205778
Head of focal point: Mr Milan Krek
The Slovenian national focal point is a part of Information Unit for Illicit Drugs (IUID) which is located at the Institute of Public Health of the Republic of Slovenia (IPH). The IPH collects, organises and analyses health-related statistical data in the fields of diagnoses, attendance, staff and visiting hours in outpatient facilities, outpatient specialist services and in hospitals. The legal basis for the establishment of the Slovenian NFP is the Prevention of Illicit Drug Abuse and Treatment of Drug Addictions Act (1999).
E-mail addresses have been inserted in a way discouraging spam. Please replace [a] by @ before actually using any of the e-mail addresses.
Drug use among the general population and young people
The European Health Interview Survey was conducted by the National Institute of Public Health in Slovenia in 2007. The sample comprised 2 117 Slovenian residents living in private households (i.e. not institutionalised) and aged 15 or over. The survey included two issues related to drug use. It reported last year prevalence among adults aged 15 and over of 2.6 % for cannabis, and 0.9 % for other drugs. More males than females used cannabis and other drugs; in the 15–64 age group, cannabis was used by 4.8 % of males and 1.3 % of females.
In 2011–12 the National Institute of Public Health implemented a survey on the use of tobacco, alcohol and other drugs among 7 514 randomly selected individuals aged 15–64 in private households. According to the survey, cannabis was the most commonly used drug in Slovenia, with lifetime prevalence of 15.8 % among all respondents, followed by cocaine and ecstasy at 2.1 % each. Last year prevalence of cannabis use among all respondents was 4.4 %, while 2.3 % reported using cannabis in the past 30 days. Lifetime cannabis use was higher among males than females, and among younger populations. Lifetime prevalence of cannabis use was 28.7 % among 15- to 34-year-olds. The highest prevalence rates for last year and last month cannabis use were among 15- to 24-year-olds (15 % and 7.5 % respectively). According to the survey results, 0.6 % of all respondents reported ever having used a new psychoactive substance.
The European School Survey Project on Alcohol and Other Drugs (ESPAD) has been carried out in Slovenia since 1995, with the latest survey in 2011. It is based on a nationwide stratified random sample of high-school students aged 15–16. As in many central and eastern European countries, an increase in lifetime experience of illicit drugs was observed in the 1990s. Lifetime experience of cannabis use nearly doubled from 13 % in 1995 to 25 % in 1999. In 2011 some 23 % reported lifetime experience of cannabis, with more males (26 %) reporting its use than females (21 %). Last year prevalence of cannabis in 2011 was 19 % and last month prevalence was 10 %. Lifetime prevalence of inhalants was reported by 20 % of the students, cocaine by 3 %, and ecstasy, amphetamines and LSD by 2 % for each drug. Lifetime prevalence of heroin use was equal to 1 %.
In 2010 Slovenia implemented the cross-national Health Behaviour in School-aged Children (HBSC) study for the third consecutive time, following previous surveys in 2002 and 2006. The study encompasses a representative sample of students aged 11, 13 and 15, although the questions pertaining to cannabis use are only asked of the 15-year-old students. The data from the latest study showed that 23 % of respondents had tried cannabis at least once in their lifetime, which is a reduction from 2002 (28 %).
A 2010 study in nightlife settings collected data on drug use from a sample of 607 respondents who visited clubs and bars. The results of the study indicated that drug use is common in Slovenian nightlife settings, and it is significantly more common among males than females.
Look for Prevalence of drug use in the 'Statistical bulletin' for more information
In Slovenia, the prevention of psychoactive substance use is regulated at the national level by laws, regulations and guidelines within various ministries, coordinated by the Ministry of Health. At the community level, Local Action Groups for addiction prevention are tasked to coordinate the activities within the competence of self-governments.
There have been a number of interventions related to environmental prevention in recent years, focused mostly on alcohol and tobacco. These interventions are implemented by various governmental and non-governmental organisations (NGOs). One example is the so-called ‘watchdog’ actions (Mystery Shopping and Yellow Card campaigns), which put formal and informal pressure on policymakers and decision-makers about the implementation of alcohol and tobacco laws (such as reporting on violations of the alcohol/tobacco marketing regulation, which bans the sale of/offering of alcohol and tobacco to minors, etc.).
Universal prevention and selective prevention have been strengthened by NGOs implementing more evidence-based, evaluated, structured and manualised prevention interventions such as Unplugged, Take Care, FreD Goes Net, EFFEKT, and PUM (Project Learning for Young Adults — a selective prevention programme for young people who drop out of school and youth at risk).
Individual or time-limited structured and semi-structured interventions that aim to build self-esteem in children and young people (especially in schools), and to improve their life (personal/social) skills, etc., are still common. In addition, evidence-based, theoretical interventions that aim to provide background support, or individual or time-limited interventions, are provided by public and private social services for families considered to be at risk (for example, therapeutic meetings between social workers or therapists and members of a family).
Prevention work in recreation settings is primarily organised by the NGO DrogArt, which offers activities at electronic music events, at youth nightlife venues and in club settings in central Slovenia, while some local projects to ensure safer nightlife through distribution of information, condoms, and occasionally also drinking water, are implemented in several Slovenian cities.
Indicated prevention programmes are chiefly aimed at children with attention deficit hyperactivity disorder (ADHD). There are also programmes for children and adolescents with other mental disorders, for example depression, and for children from families where parents or grandparents use psychoactive substances, and Roma communities.
In 2012 recommendations for school-based prevention were issued by one NGO, based on literature reviews and the evaluation of Unplugged. These recommendations have not been accepted at a national level.
See the Prevention profile for Slovenia for more information.
High-risk drug use
Up to 2012 the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) defined problem drug use as injecting drug use (IDU) or long duration/regular use of opiates, cocaine and/or amphetamines. However, in 2012 a new definition of ‘high-risk drug use’ was adopted. This new definition includes ‘problem drug use’, but is broader (mainly in its inclusion of high-risk use of more substances). Details are available here.
In Slovenia, opiates, and in particular heroin, are the most reported substance linked to high-risk drug use, according to various data sources including treatment demand data and harm reduction data. The most recent (2012) estimate used capture–recapture methodology and indicated that there were 6 917 high-risk opioid users (range: 6 011–8 114) in Slovenia, which translates to a rate of 4.91 (range: 4.27–5.76) per 1 000 inhabitants aged 15–64.
High-risk cannabis use was calculated based on data from the 2011 and 2012 general population studies on the use of tobacco, alcohol and other drugs. They indicate that about 0.5 % of those aged 15–64 were using cannabis daily or almost daily.
Look for High risk drug-use in the Statistical bulletin for more information.
Treatment demand data in Slovenia is collected through the nationwide network of the Centres for the Prevention and Treatment of Drug Addiction (CPTDA) and from the Centre for the Treatment of Drug Addiction at the Ljubljana Psychiatric Hospital. In 2013, a new Treatment Demand Questionnaire 3.0 was introduced and 17 outpatient drug treatment centres (out of 18 CPTDAs) submitted treatment demand data. The Centre for the Treatment of Drug Addiction at the Ljubljana Psychiatric Hospital did not participate in TDI data collection in 2013. The total number of reported clients entering treatment in 2013 was 290, of which 95 had entered treatment for the first time. Data are not reported from prisons and low-threshold agencies, as data collection is not yet implemented in those facilities.
In 2013 some 81 % of all treatment clients reported opioids, mainly heroin, as their primary drug, 13 % reported cannabis and 3 % cocaine. Among new treatment clients 60 % reported opioids, mainly heroin, as their main problem substance, followed by 32 % for cannabis and 6 % for cocaine. In general, the proportion of those who entered treatment because of cannabis use increased among new clients entering treatment, and also among all clients entering treatment. Drug injecting was reported less frequently among new treatment clients than among all clients entering treatment (34 % and 48 % respectively), and in general during the last seven years there has been a declining tendency in drug injecting among all and new treatment entrants.
The mean age of all treatment clients entering treatment was 32 years, while new treatment clients were on average slightly younger at 29 years old. In general, the ageing of drug using population, which is also noted in Slovenia, presents new issues and problems such as increased social hardship, including homelessness and a higher frequency of acute and chronic illness. With regard to gender distribution, 81 % of all and 80% of new treatment clients were male.
Look for Treatment demand indicator in the Statistical bulletin for more information.
Drug-related infectious diseases
The National Institute of Public Health of the Republic of Slovenia collects data on the prevalence of human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) infection in convenience samples of people who inject drugs (PWID) through a national network of CPTDAs. In addition, unlinked, anonymous HIV testing of PWID is performed the first time they attend treatment at the Centre for Prevention and Treatment of Illicit Drug Addiction in Ljubljana and at four non-governmental harm reduction programmes. The National Institute of Public Health of the Republic of Slovenia also collects information on newly diagnosed cases of HIV, HBV and HCV infections. In contrast to HIV, where information on the mode of infection is available for almost all notified cases, information on the transmission route is available only for a minority of notified cases of HBV and HCV.
Available data for 2006–13 indicate that HIV prevalence among PWID confidentially tested during treatment at CPTDAs remained below 1 %, except in 2009, 2011 and 2013 when it rose to 1.3 %, 1.9 % and 1.4 % respectively. In addition, saliva specimens collected for unlinked anonymous testing for surveillance purposes at different sentinel sites between 2008and 2013 found in total three specimens that were positive for HIV antibodies in 2010 (sample of 253), 2011 (sample of 186) and 2012 (sample of 173), corresponding to annual prevalence rates of 0.4 %, 0.5 % and 0.6 % respectively. In the last few years three new HIV cases with a history of injecting drug use were reported — one in 2012 and two in 2013, while between 2001 and 2011 no new HIV infection cases were reported among PWID.
In 2013, the prevalence of antibodies against HBV among PWID confidentially tested during their treatment at CPTDAs was 5.6 %, and the prevalence against HCV was 32.1 %. Between 2009 and 2013 the prevalence of those infected with HBV was the highest in 2011 (8.1 %), while for hepatitis C it was highest in 2013.
The reported rate of acute and chronic HBV infection in the Slovenian population in 2013 was 2.5 per 100 000 inhabitants. During 2008–13 the reported incidence rate ranged from 3.4 per 100 000 inhabitants in 2011 to a low of 2.0 per 100 000 inhabitants in 2011. The reported rate of acute and chronic HCV infection in the Slovenian population in 2013 was 4.3 per 100 000 inhabitants. The reported rate of HCV infection ranged from the highest at 5.4 per 100 000 inhabitants in 2009 to a low of 4.1 per 100 000 inhabitants in 2008. However, there is a high risk of underreporting of cases for both HCV and HBV.
Look for Drug-related infectious diseases in the Statistical bulletin for more information.
Drug-induced deaths and mortality among drug users
In 2013 information on drug-related deaths was reported based on data from the General Mortality Register of the National Institute for Public Health. The data are extracted following EMCDDA definitions and recommendations.
There were 28 drug-induced deaths in 2013, similar to the figures for 2009–12 but less than in 2007–08. The majority of deaths were among males (20), and the mean age was 37.1 years. For 20 cases toxicological findings were reported. Results showed the involvement of opioids (heroin, methadone and other opioids) in the vast majority of the reported cases.
The drug-induced mortality rate among adults (15–64) was 19.9 deaths per million in 2013, comparable to the European average of 17.2 deaths per million.
A mortality cohort study conducted from 2004 to 2013 among treated drug users indicated a mortality rate of 5.7 deaths per 1 000 person-years, a rate that is two times higher than the general population of the same age. The average age at death was 38 for men and 34 for women. Apart from drug-induced deaths, the excess mortality was due to suicide, traffic accidents and other violent acts, alcoholic liver cirrhosis and cardiovascular diseases. The excess mortality due to suicides was particularly high — 2.5 times higher for males and almost four times higher for females in the cohort compared to the general population.
Look for Drug-related deaths in the Statistical bulletin for more information.
At the national level, drug-related treatment is provided by different systems of health, social support and civil society NGOs. Responsibility for implementing treatment lies predominantly at the national level. Treatment is carried out on a formal legal basis under the following acts: the Health Care and Health Insurance Act (Official Gazette 9/92), Production and Trade in Illicit Drugs Act (official Gazette 108/99 with amendments) and the Prevention of the Use of Illicit Drugs and Dealing with Consumers of Illicit Drugs Act (Official Gazette 98/99).
The main funder of drug-related treatment in the health sphere is the Health Insurance Institute of Slovenia. The public sector delivers most drug-related treatment, primarily opioid substitution treatment (OST). However, other drug-related treatment (mainly psychosocial interventions) is also delivered by NGOs, supported by public funding. In terms of government funding for new treatment methods, priority is given to abstinence-based treatment, or treatment that reduces the harmful health consequences related to drug use. The Ministry of Labour, Family, Social Affairs and Equal Opportunities co-funds rehabilitation services.
Drug-related treatment is available free of charge within the framework of the public health national service network. Treatment takes place primarily at one of the 18 CPTDAs, which are run as a public health service. The legislative basis of the work of the CPTDAs and the provision of drug-related health services are defined in four laws: the Law on the Prevention of Illicit Drug Use and Treatment of Drug Users; the Law on Health Care and Health Insurance; the Law on Drugs and Medicine Accessories; and the Law on the Health Service. To provide inpatient treatment, the government has established a public health centre — the Centre for the Treatment of Drug Addiction — at the Ljubljana Psychiatric Hospital. All treatment programmes are under the supervision of the Health Council.
The Commission for Controlling the Work of the CPTDAs, appointed by the Minister of Health, oversees the treatment centres. This Commission checks the documentation, human resources and equipment of the centres, the scope of work performed, their methadone maintenance treatment programmes and consultation-based treatment.
The treatment system in Slovenia has four categories: (i) outpatient treatment; (ii) inpatient treatment; (iii) detoxification; and (iv) OST. Outpatient treatment is used for the majority of treated drug users, and the most frequent treatment is OST. Treatment also includes psychosocial interventions, other medically assisted treatment, individual or group counselling and a socio- or psychotherapy component, including assistance in rehabilitation and social reintegration, links to home nursing, therapeutic communities and self-help groups. Inpatient drug treatment consists mainly of psychosocial interventions, yet may also be pharmacologically assisted in terms of withdrawal treatment. Detoxification treatment may take place in inpatient or outpatient settings. Inpatient treatment sessions last six to eight weeks. In 2009 an integrated treatment for drug users with mental co-morbidities was made available at the Psychiatric Hospital of Ljubljana.
OST was introduced in 1990, and is provided either by doctors employed in outpatient clinics or by general practitioners who practise at the CPTDAs. Buprenorphine was registered in 2004 and slow-release morphine in 2005. These two medications have contributed to the increased diversification of OST options. Treatment with naltrexone is also available. The buprenorphine/naloxone combination was introduced in 2007.
In 2013 the total number of clients in OST was estimated to be 3 261, of which 2 024 received methadone maintenance treatment while others received either buprenorphine-based substitution treatment, suboxone or slow-release morphine.
See the Treatment profile for Slovenia for additional information.
Harm reduction responses
Slovenia has more than 20 years of experience in the field of harm reduction. The reduction of drug-related harm was included in the National Strategy on Drugs for 2004–09 and was continued in the National Strategy for 2010–14. Many new programmes have been developed at the local level, mainly aimed at injecting drug users and drug users in recreational settings. As an example, in response to the recently emerging use of unknown substances sold as drugs, the NGO DrogaArt provides a special testing service in recreational settings.
In 2013, ten harm reduction programmes (including four mobile units) for people who inject drugs operated across Slovenia, providing sterile injecting equipment, information and counselling at nine fixed sites and 178 different outreach locations across Slovenia, including the capital city of Ljubljana and other regions and cities (the Maribor region, the Koper region, the cities of Celje, Ilirska Bistrica, etc.). Injecting equipment for these programmes is centrally purchased and distributed by the Koper Regional Unit of the National Institute for Public Health and funded the Slovenian Health Insurance Institute. Syringes and other injecting paraphernalia (alcohol wipes, ascorbic acid) are usually made available through day-care centres, outreach and mobile services, but are also available at five pharmacy-based exchange sites. In 2013, around 513 000 syringes were distributed nationwide. It was estimated in 2012 that around 121 000 syringes were sold to drug users through pharmacies.
In addition, free vaccination against HBV and free testing for HCV and HIV are available to all drug users in contact with the CPTD. These centres also provide training on overdose prevention. Treatment for HCV infection is also free of charge.
See the Harm reduction overview for Slovenia for additional information.
Drug markets and drug-law offences
Slovenia is located on the Balkan route, the main pathway for illegal trafficking of heroin and cannabis from south-eastern Europe to central and western Europe, while synthetic stimulants and cocaine are smuggled in the opposite direction. Small amounts of the trafficked illicit drugs are diverted to the Slovenian market, which is organised by small criminal groups with good connections to their peers in other Western Balkan countries. These groups are also becoming increasingly involved in the cultivation of cannabis within Slovenia. Some indications exist that stimulants are smuggled into Slovenia from western European countries (the Netherlands), as no production sites for these substances have so far been found inside Slovenia.
Ministry of Interior data shows that 6 388 drug-law offences were reported in 2013, of which 66 % were use-related offences. More than half of the criminal offences and minor offences related to the production and trade of drugs were linked to cannabis.
It is notable that in 2013 the number of seizures of most illicit drugs increased when compared to 2012, with the exception of heroin and cocaine. The only drugs that were seized in greater quantities in 2013 than in 2012 were amphetamine, methamphetamine, herbal cannabis and ecstasy. In 2013, a new record amount of herbal cannabis (809.59 kg; 706 kg in 2012) was seized. Record amounts of amphetamine (15.12 kg) and methamphetamine (0.54 kg) were seized in 2013. In 2009, the number of ecstasy tablets seized was the second highest in the last decade, but in 2010–12 there was a significant reduction in the number seized. In 2013, the number of ecstasy tablets seized slightly exceeded the level of 2012, but 0.85 kg of powder was also seized.
Around 70 cannabis cultivation sites were discovered in 2013, and although an upward trend in the number of cultivation sites seems to be stabilising there are indications that cannabis cultivation is continuing to increase. The total number of cannabis plants seized in 2013 was 9 515; these relate to 212 seizures.
The number of heroin-related seizures has declined since 2008 from 772 to 339 in 2013. The quantity seized has also reduced from 136.5 kg in 2008 to 7.6 kg in 2013, while significant annual fluctuations are recorded, but at lower levels than before 2011.
Although the number of cocaine seizures remains fairly stable, the amounts seized fluctuate — in 2012 a total of 26.82 kg of cocaine was seized, which followed a period from 2009 to 2011 when the annual amount seized was about 2 kg, but in 2013 the amounts seized fell to 3.314 kg.
Look for Drug law offences in the Statistical bulletin for additional data.
National drug laws
In Slovenia, purchasing drugs for one’s own use and consumption is not considered a criminal offence. Slovenia’s Production and Trade in Illicit Drugs Act defines separately the possession of illicit drugs, the possession of a small quantity for individual use, and the possession of a small quantity for individual use for a person who opts for medical treatment or treatment in health or social programmes. Possession of an illicit drug is considered a minor offence under the Production and Trade in Illicit Drugs Act (Article 33), and is subject to a fine. For example, possession of small quantities of illicit drugs for one-off personal use might lead to a monetary fine of between EUR 42 and EUR 209. Individuals may be subject to more lenient punishment if they voluntarily enter treatment for illicit drug use or social security programmes approved by the Health Council at the Ministry of Health or by the Council for Drugs at the Ministry of Labour.
The Penal Code, adopted in 2008, defines two criminal offences: the manufacture and trafficking of illicit drugs (Article 186), and facilitating the consumption of illicit drugs (Article 187). Article 186 includes the sale of illicit drugs, the manufacture of illicit drugs, the purchase of illicit drugs with the intention of sale, possession with the intent to re-sell, etc., punishable by 1–10 years’ imprisonment, or 3–15 years if the offence included defined aggravating circumstances such as particular locations or involving vulnerable people.
Article 187 of the Penal Code includes the offer of illicit drugs for consumption, the offer of premises for minors to consume illicit drugs, etc. as offences punishable by prison sentences of between six months and eight years. Offences committed on vulnerable people, and where an offender is abusing their position, are punishable by 1–12 years’ imprisonment. The Penal Code was amended in November 2011 to provide that an action to facilitate illicit drug use is not punishable if it is in the context of a programme of drug addiction treatment or is a controlled use of drugs that conforms to the law approved and is implemented within the framework or under the supervision of public health authorities, for example in a drug consumption room. In principle, this new amendment creates an enabling legal environment for the establishment of drug consumption rooms in Slovenia.
In 2013 some 48 new psychoactive substances, mostly new synthetic drugs, were added to the list of controlled substances.
Go to the European Legal Database on Drugs (ELDD) for additional information.
National drug strategy
On 2 April 2014 Slovenia’s National Assembly adopted a new resolution on the National Programme on Drugs for 2014–20. The new National Programme is a continuation of the previous strategy and is based on the findings of its evaluation; it also takes into account the current epidemiological situation in the country. The main emphasis in the new National Programme is the development of integral and balanced measures, programmes and activities that contribute to solving the problem of illicit drugs in Slovenia. Since this field is covered by several ministerial departments and by various disciplines, the National Programme includes both supply reduction and activities and measures related to prevention, treatment and social care.
The National Programme specifies a number of goals, including:
- The promotion of prevention programmes in order to reduce the number of new drug users among the younger generation and to reduce the number of offences related to illicit drugs.
- Support for the development of programmes to help maintain or reduce the number of people infected with HIV, HBV and HCV, and deaths due to overdoses.
- The development of programmes for the psychosocial treatment of drug users, therapeutic communities and communes, and re-integration programmes for former drug users.
- The development and upgrading of all the coordinating structures in the drug field at local and national levels.
- Strengthening of the activities against organised crime, the illicit drug trade, money laundering and other drug-related crime.
The National Programme is built around six pillars: (i) information systems; (ii) drug demand reduction; (iii) supply reduction; (iv) international cooperation; (v) coordination; and (vi) evaluation, research and training/education. The Programme includes a requirement for a process evaluation of its implementation and a final evaluation.
Part of the strategic document the National Crime Prevention and Crime Control Strategy also covers the area of illicit drugs. Several objectives in this strategy are concerned with drug issues:
- Ensure the successful detection of criminal acts and offences in the field of illicit drugs.
- Reduce the number of all illicit drug users.
- Strengthen universal, selective and indicated prevention activities aimed at preventing drug use and reducing drug-related crime.
These objectives are to be achieved through a series of specific measures. These include monitoring organised crime groups and targeting their activities. In order to reduce the number of illicit drug users, efforts are to be directed at creating a better living environment, alleviating the negative consequences of drug use through access to treatment, social care and reintegration, provision of mental health services, and the prevention of HIV infections. The strategy seeks to deploy a range of prevention programmes at the universal, selective and indicative levels in order to target the general population as well as individuals deemed to be more at risk of drug use.
Coordination mechanism in the field of drugs
Inter-ministerial coordination of drug policy is the responsibility of the Government Commission for Drugs of the Republic of Slovenia. The Commission on Narcotic Drugs of the Government of Slovenia is responsible for drug policy at the inter-ministerial level. The Commission promotes and coordinates government policy and programmes, proposes measures, and monitors implementation of the provisions of international conventions. It includes representatives from the Ministry of Health, Ministry of Interior, Ministry of Education, Science and Sport, Ministry of Labour, Family Social Affairs and Equal Opportunities, Ministry of Justice, Ministry of Finance, Ministry of Defence, Ministry of Agriculture and Environment and Ministry of Foreign Affairs. When preparing an expert basis for decision-making, the Commission may invite independent experts to participate. The Ministry of Health performs the administrative work of the Commission.
Two Ministries carry out the operational day-to-day coordination of drug policy in Slovenia: the Ministry of Health is responsible for coordination activities in the areas of demand reduction, legislation and drug policy; and the Ministry of Interior is responsible for coordinating responses in the area of supply reduction.
At the Ministry of Health, the Health Promotion and Healthy Lifestyles Division is responsible for the day-to-day coordination of drug policy. This Division, part of the Public Health Directorate, took over the tasks of the Government Office for Drugs, which was phased out between 2004 and 2007, during which time its functions transferred to the Ministry of Health.
Local Action Groups (LAGs) are tasked with the coordination of drug policy at the local level. The Action Groups act as expert advisory bodies for mayors and municipal/urban councils responsible for preparing measures in the drugs area. Ten regional coordinators were appointed in 2005. A wide variety of non-professional groups are members of the Action Groups. These include representatives from municipalities, kindergartens, schools, parents, youth, drug users, health centres, centres for social work, employment services, police, courts, NGOs (especially youth centres, clubs, and sports and cultural organisations), religious communities, media and other interested members of the public. This broad composition reflects the wide scope of activities the Action Groups undertake, which extends beyond the drugs field.
In Slovenia there are no budgets attached to the national drug policy documents. Authorities report total drug-related expenditures (1) every year, covering both demand and supply reduction activities, but the methodology used is not detailed and data completeness varies every year.
In 2013, data available for total drug-related expenditures suggested that it represented 0.03 % of gross domestic product (GDP). Taking into account data limitations, available estimates suggest that these expenditures varied between 0.023 % and 0.030 % of GDP during the period 2006–13.
Trend analysis shows that drug-related labelled expenditure increased between 2006 and 2011 in nominal terms. However, after 2008 the pace of growth decelerated, probably associated with the public austerity measures following the economic recession of 2008. Despite the fact that annual data is not fully comparable, evidence seems to suggest that the total funds available may have registered a reduction in 2012, following the overall public austerity experienced in Slovenia, and remained stable in the subsequent year.
- (1) Some of the funds allocated by governments for expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, the bulk of drug-related expenditure is not identified (‘unlabelled’) and must be estimated by modelling approaches. The total budget is the sum of labelled and unlabelled drug-related expenditures.
The new National Programme on Drugs for 2014–20 was adopted in 2014, and includes a chapter on research, evaluation and education.
ESPAD and HBSC surveys have been regularly implemented in Slovenia. The national focal point is one of the agencies involved in drug-related research, and also plays an important role in collecting and disseminating research findings at the national level. The main focus of drug-related research is population surveys, although applied research in the treatment area and pharmacological research projects are also undertaken. Recent drug-related studies mentioned in the 2014 Slovenian National report mainly focused on aspects related to the prevalence, incidence and patterns of drug use.
See Drug-related research for more detailed information.
Key national figures and statistics
b Break in time series.
p Eurostat provisional value.
1 Gross domestic product (GDP) is a measure of economic activity. It is defined as the value of all goods and services produced less the value of any goods or services used in their creation. The volume index of GDP per capita in Purchasing Power Standards (PPS) is expressed in relation to the European Union (EU-27) average set to equal 100. If the index of a country is higher than 100, this country's level of GDP per head is higher than the EU average and vice versa.
2 Expenditure on social protection contains: benefits, which consist of transfers, in cash or in kind to households and individuals to relieve them of the burden of a defined set of risks or needs.
3 Unemployment rates represent unemployed persons as a percentage of the labour force. Unemployed persons comprise persons aged 15 to 74 who were: (a) without work during the reference week; (b) currently available for work; (c) actively seeking work.
4 Situation of penal institutions on 1 September, 2012.
5 Share of persons aged 0+ with an equivalent disposable income below the at-risk-of-poverty threshold, which is set at 60 % of the national median equivalised disposable income (after social transfers).
| ||Year ||Slovenia ||EU (28 countries) ||Source |
|Population || 2014 ||2 061 085 ||506 824 509 ep |
|Population by age classes ||15–24 || 2014 ||10.1 % ||11.3 % bep |
|25–49 ||36.3 % ||34.7 % bep |
|50–64 ||21.5 % ||19.9 % bep |
|GDP per capita in PPS (Purchasing Power Standards) 1 || 2013 ||82 ||100 ||Eurostat |
|Total expenditure on social protection (% of GDP) 2 || 2012 ||25.4 p ||29.5 % p ||Eurostat |
|Unemployment rate 3 || 2014 ||9.7 % ||10.2 % ||Eurostat |
|Unemployment rate of population aged under 25 years || 2014 ||20.2 % ||22.2 % ||Eurostat |
|Prison population rate (per 100 000 of national population) 4 || 2012 ||66.1 || : ||Council of Europe, SPACE I-2013 |
|At risk of poverty rate 5 || 2013 ||14.5 % ||16.6 % ||SILC |
Data sheet — key statistics on the drug situation
| || || || ||EU range || || || |
| ||Year || ||Country data ||Min. ||Max. ||Average ||Rank ||Reporting Countries |
|Opioids || || || || || || || || |
|Problem opioid use (rate/1 000) ||2012 ||1 ||4.91 ||0.2 ||10.7 || ||16 ||21 |
|All clients entering treatment (%) ||2013 || ||81.5% ||6% ||93% || || || |
|New clients entering treatment (%) ||2013 || ||60.6% ||2% ||81% || || || |
|Purity — heroin brown (%) ||2013 || ||9.0% ||6% ||42% || ||3 ||24 |
|Price per gram — heroin brown (EUR) ||2013 ||2 ||EUR 40 ||EUR 25 ||EUR 158 || ||7 ||22 |
| || || || || || || || || |
|Cocaine || || || || || || || || |
|Prevalence of drug use — schools (%) ||2011 || ||3.0% ||1% ||5% || || || |
|Prevalence of drug use — young adults (%) ||2012 || ||1.2% ||0% ||4% ||2% || || |
|Prevalence of drug use — all adults (%) ||2012 || ||0.5% ||0% ||2% ||1% ||12 ||26 |
|All clients entering treatment (%) ||2013 || ||3.5% ||0% ||39% || || || |
|New clients entering treatment (%) ||2013 || ||6.4% ||0% ||40% || || || |
|Purity (%) ||2013 || ||51.4% ||20% ||75% || ||20 ||27 |
|Price per gram (EUR) ||2013 ||3 ||EUR 60 ||EUR 47 ||EUR 103 || ||10 ||24 |
| || || || || || || || || |
|Amphetamines || || || || || || || || |
|Prevalence of drug use — schools (%) ||2011 || ||2.0% ||1% ||7% || || || |
|Prevalence of drug use — young adults (%) ||2012 || ||0.8% ||0% ||3% ||1% || || |
|Prevalence of drug use — all adults (%) ||2012 || ||0.3% ||0% ||1% ||1% ||7 ||25 |
|All clients entering treatment (%) ||2013 || ||0.7% ||0% ||70% || || || |
|New clients entering treatment (%) ||2013 || ||1.1% ||0% ||22% || || || |
|Purity (%) ||2013 || ||8.7% ||5% ||71% || ||6 ||25 |
|Price per gram (EUR) ||2013 ||3 ||EUR 10 ||EUR 8 ||EUR 63 || ||6 ||21 |
| ||: || ||: || || || || || |
|Ecstasy ||: || ||: || || || || || |
|Prevalence of drug use — schools (%) ||2011 || ||2.0% ||1% ||4% || || || |
|Prevalence of drug use — young adults (%) ||2012 || ||0.8% ||0% ||3% ||1% || || |
|Prevalence of drug use — all adults (%) ||2012 || ||0.3% ||0% ||2% ||1% ||6 ||25 |
|All clients entering treatment (%) ||2013 || ||: ||0% ||2% || || || |
|New clients entering treatment (%) ||2013 || ||: ||0% ||4% || || || |
|Purity (mg of MDMA base per unit) ||2013 || ||82 mg ||26 mg ||144 mg || ||10 ||23 |
|Price per tablet (EUR) ||2013 ||3 ||EUR 5 ||EUR 3 ||EUR 24 || ||5 ||19 |
| || || || || || || || || |
|Cannabis || || || || || || || || |
|Prevalence of drug use — schools (%) ||2011 || ||23.0% ||5% ||42% || || || |
|Prevalence of drug use — young adults (%) ||2012 || ||10.3% ||0% ||22% ||12% || || |
|Prevalence of drug use — all adults (%) ||2012 || ||4.4% ||0% ||11% ||6% ||14 ||27 |
|All clients entering treatment (%) ||: || ||12.5% ||3% ||63% || || || |
|New clients entering treatment (%) ||: || ||31.9% ||5% ||80% || || || |
|Potency — herbal (%) ||2013 || ||7.5% ||2% ||13% || ||8 ||22 |
|Potency — resin (%) ||2013 || ||5.8% ||3% ||22% || ||2 ||20 |
|Price per gram — herbal (EUR) ||2013 ||2 ||EUR 4 - EUR 10 ||EUR 4 ||EUR 25 || || || |
|Price per gram — resin (EUR) ||2013 ||2 ||EUR 7 - EUR 20 ||EUR 3 ||EUR 21 || || || |
| || || || || || || || || |
|Prevalence of problem drug use || || || || || || || || |
|Problem drug use (rate/1 000) ||: || ||: ||2.0 ||10.0 || || || |
|Injecting drug use (rate/1 000) ||: || ||: ||0.2 ||9.2 || || || |
| || || || || || || || || |
|Drug-related infectious diseases/deaths || || || || || || || || |
|HIV infections newly diagnosed (rate/million) ||2013 || ||1.0 ||0.0 ||54.5 || || || |
|HIV prevalence (%) ||2013 || ||1.4% ||0% ||49% || || || |
|HCV prevalence (%) ||2013 || ||32.1% ||14% ||84% || || || |
|Drug-related deaths (rate/million) ||2013 || ||13.6 ||1.5 ||84.1 || || || |
| || || || || || || || || |
|Health and social responses || || || || || || || || |
|Syringes distributed ||2013 || ||513 272 ||124 406 ||9 457 256 || || || |
|Clients in substitution treatment ||2013 || ||4 065 ||180 ||172 513 || || || |
| || || || || || || || || |
|Treatment demand || || || || || || || || |
|All clients ||2013 || ||290 ||289 ||101 753 || || || |
|New clients ||2013 || ||95 ||19 ||35 229 || || || |
|All clients with known primary drug ||2013 || ||287 ||287 ||99 186 || || || |
|New clients with known primary drug ||2013 || ||94 ||19 ||34 524 || || || |
| || || || || || || || || |
|Drug law offences || || || || || || || || |
|Number of reports of offences ||2013 || ||5 329 ||429 ||426 707 || || || |
|Offences for use/possession ||2013 || ||4 010 ||58 ||397 713 || || || |